Beyond The Numbers: 5 Analysts Discuss Kenvue Stock
Portfolio Pulse from Benzinga Insights
Analysts have recently provided mixed reviews on Kenvue (NYSE:KVUE), with sentiments ranging from bullish to bearish over the past three months. The average 12-month price target for KVUE is now $22.4, a decrease from the previous $24.00. Kenvue, a spin-off from Johnson & Johnson and the world's largest pure-play consumer health company, has seen a revenue decline of -2.68% as of December 31, 2023, but maintains strong financial health indicators such as net margin and ROE.
April 03, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Kenvue has received mixed analyst ratings with a lowered average price target of $22.4. Despite a slight revenue decline, its strong financial health indicators suggest resilience.
The mixed analyst ratings and the decrease in the average price target could lead to short-term uncertainty in KVUE's stock price. However, the company's strong financial health indicators, such as net margin and ROE, alongside its position as a leader in the consumer health sector, suggest a potential for resilience and stability in the longer term. The recent revenue decline is a concern but may be offset by the company's overall strong performance and market position.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100